A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Plonmarlimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors I-MAB Biopharma
Most Recent Events
- 02 Aug 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 02 Aug 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2023.
- 17 Aug 2020 According to an I-MAB Biopharma media release, first patient has been dosed.